We are live on ! Find out more
LBRX

LB Pharmaceuticals
LBRX

68 hedge funds and large institutions have $552M invested in LB Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

106% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 16

75% more capital invested

Capital invested by funds: $315M → $552M (+$237M)

28% more funds holding

Funds holding: 53 → 68 (+15)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

1.19% less ownership

Funds ownership: 99.18% → 97.99% (-1.2%)

Holders
68
Holders Change
+15
Holders Change %
+28.3%
% of All Funds
0.83%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
33
Increased
13
Reduced
12
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19.4M
3
JP Morgan Chase
JP Morgan Chase
New York
+$10.1M
4
RCM
RA Capital Management
Massachusetts
+$7.54M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.47M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$8.5M
2
SCM
Soleus Capital Management
Connecticut
-$6.81M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.44M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.74M
5
Marshall Wace
Marshall Wace
United Kingdom
-$4.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
26
HighVista Strategies
Massachusetts
$3.12M +$2.45M +140,107 New
IHAM
27
Integral Health Asset Management
New York
$2.23M – – –
LF
28
Longbow Finance
Switzerland
$1.83M +$1.44M +82,336 New
BCM
29
Boxer Capital Management
California
$1.56M – – –
UBS Group
30
UBS Group
Switzerland
$1.13M +$867K +49,658 +4,707%
Bank of America
31
Bank of America
North Carolina
$974K +$735K +42,058 +2,474%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$902K +$708K +40,517 New
Jane Street
33
Jane Street
New York
$706K +$24.2K +1,388 +5%
Barclays
34
Barclays
United Kingdom
$673K -$10.9K -624 -2%
ACP
35
Acuta Capital Partners
California
$668K – – –
Morgan Stanley
36
Morgan Stanley
New York
$549K +$263K +15,036 +157%
N
37
Nuveen
North Carolina
$511K +$401K +22,966 New
Wells Fargo
38
Wells Fargo
California
$496K +$372K +21,303 +2,130%
Focus Partners Wealth
39
Focus Partners Wealth
Massachusetts
$447K +$351K +20,095 New
Norges Bank
40
Norges Bank
Norway
$445K +$349K +20,000 New
XT
41
XTX Topco
Cayman Islands
$426K +$137K +7,845 +70%
Marshall Wace
42
Marshall Wace
United Kingdom
$401K -$4.15M -237,512 -93%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$362K +$284K +16,283 New
Deutsche Bank
44
Deutsche Bank
Germany
$296K +$232K +13,298 New
Two Sigma Investments
45
Two Sigma Investments
New York
$283K -$13.6K -780 -6%
JFG
46
Jefferies Financial Group
New York
$277K -$11.4K -655 -5%
MIM
47
MetLife Investment Management
New Jersey
$247K +$194K +11,104 New
T. Rowe Price Associates
48
T. Rowe Price Associates
Maryland
$247K -$4.74M -271,570 -96%
Invesco
49
Invesco
Georgia
$244K +$191K +10,955 New
SCM
50
Soleus Capital Management
Connecticut
$223K -$6.81M -390,000 -98%
1
2
3 4

LBRX Hedge Fund Activity: Q4 2025 in Review

68 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q4 2025, worth a combined $552M — up 75% from $315M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new LBRX positions and 16 closed out — a net gain of 17 holders — while 13 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $22.1M. The largest seller was Millennium Management, exiting entirely with an estimated $8.5M sold.

  • 68 institutional investors held LB Pharmaceuticals (LBRX) as of Q4 2025, up from 53 in Q3 2025.
  • Funds reported $552M of LB Pharmaceuticals stock for Q4 2025, up 75% quarter-over-quarter.
  • 33 funds opened new LB Pharmaceuticals positions in Q4 2025 and 16 closed out, a net change of +17 holders.
  • The largest LB Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $22.1M added.
  • The largest LB Pharmaceuticals seller in Q4 2025 was Millennium Management, an estimated $8.5M sold.

Based on aggregated 13F filings for Q4 2025.